Gastroenterology News and Research

RSS

Gastroenterology is the branch of medicine where the digestive system and its disorders are studied.

New interventional technique effective for controlling hepatic arterial hemorrhage after PD

Delayed hepatic arterial hemorrhage after pancreaticoduodenectomy (PD) is not a common but a fatal complication, occurring in 7% of all patients. Its ideal management remains unclear and controversial. A research article published on August 7, 2010 in the World Journal of Gastroenterology addresses this question. The authors reported the clinical outcome of 9 patients with life-threatening hemorrhage from a ruptured hepatic artery pseudoaneurysm after PD after treatment with a new interventional technique, namely placement of stent-grafts.

21 Sep 2010

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined.

21 Sep 2010

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement. The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia, Humira and Remicade utilized in the treatment of Crohn's Disease, and the subsequent development of diagnostic tests.

17 Sep 2010

Sun Pharmaceutical announces expiration of Tender Offer for purchase of Taro Pharmaceutical shares

Sun Pharmaceutical Industries Ltd. today announced the expiration of the Tender Offer by Sun's subsidiary, Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), to purchase all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro) for $7.75 per Ordinary Share.

15 Sep 2010

Arthritis Foundation, Takeda launch Gout Living educational campaign

The Arthritis Foundation and Takeda Pharmaceuticals North America, Inc., announced the launch of a new educational campaign, Gout Living, to help increase understanding and encourage better management of gout.

14 Sep 2010

Merit Medical Systems acquires BioSphere Medical

Merit Medical Systems, Inc. today announced the completion of its acquisition of BioSphere Medical, Inc., a leading developer and marketer of embolotherapeutic products for the treatment of uterine fibroids, hypervascularized tumors, and arteriovenous malformations.

13 Sep 2010

IASIS Healthcare signs agreement to acquire Brim Holdings

IASIS Healthcare today announced the signing of a definitive agreement to acquire Brim Holdings, Inc., which operates Wadley Regional Medical Center in Texarkana, Texas, and Pikes Peak Regional Hospital in Woodland Park, Colorado, in a cash-for-stock transaction valued at approximately $95 million, subject to customary closing conditions and working capital adjustments. Combined revenue of the two facilities is approximately $120 million.

10 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

Spirus Medical obtains Japanese marketing approval for ENDO-EASE line of endoscopy devices

Spirus Medical announced today that it has obtained marketing approval from the Japanese Ministry of Health, Labor and Welfare for the company's proprietary ENDO-EASE line of endoscopy devices. The Endo-Ease Endoluminal Advancement System features novel "over-tubes" that use a spiral design utilizing simple rotation to facilitate enteroscopy, colonoscopy and ileoscopy.

9 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

NIH expands funding for Baylor College of Medicine Human Microbiome Project

The National Institutes of Health today announced expanded funding of the Baylor College of Medicine Human Microbiome Project clinical program initiated last year at Texas Children Hospital.

8 Sep 2010

Israeli Supreme Court dismisses Taro's appeal in favor of Sun Pharma

Sun Pharmaceutical Industries Ltd. today announced that the Supreme Court of Israel has unanimously dismissed the appeal by Taro Pharmaceutical Industries Ltd. of the previous ruling by the Tel-Aviv District Court holding that the Israeli special tender offer (STO) rules do not apply to the Tender Offer by Sun's subsidiary, Alkaloida Chemical Company Exclusive Group Ltd., to purchase all outstanding Ordinary Shares of Taro for USD 7.75 net per Ordinary Share in cash.

8 Sep 2010

GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced data with the EndoBarrier Gastrointestinal Liner at 12 months showing significant weight loss and cardiovascular and metabolic improvements in obese patients.

7 Sep 2010

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. The proposed indication would make TMC278 available for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults.

3 Sep 2010

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

2 Sep 2010

Researchers dispute study findings that show greater incidence of surgery for children with CD

A new multi-center study of 854 children with Crohn's disease shows a 5-year cumulative risk of bowel surgery is significantly lower than reported in recent studies. The findings of the study, led by Hasbro Children's Hospital, also indicate that children diagnosed between ages 13 and 16 had an increased risk of bowel surgery, and that a common treatment that begins at diagnosis, immunomodulator therapy, did not alter the risk of surgery.

2 Sep 2010

GI Dynamics, Elemental Healthcare sign agreement for distribution of EndoBarrier Gastrointestinal Liner

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced it has entered into a new agreement with Elemental Healthcare, based in Hungerford, Berkshire, for the distribution of the EndoBarrier Gastrointestinal Liner in England, Wales, Scotland, Northern Ireland and Ireland.

2 Sep 2010

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules.

2 Sep 2010

Tooth brush in a teenager’s stomach

A 15-year-old girl in New Zealand came to the emergency department at an Auckland hospital after accidentally swallowing her 19-centimetre toothbrush. The case study was published in the New Zealand Medical Journal.

31 Aug 2010

Study: IV ibuprofen decreases pain, morphine use in pre and post-operative orthopedic surgery patients

Cumberland Pharmaceuticals Inc. today announced the publication of new data supporting the safety and efficacy of Caldolor® (ibuprofen) Injection in pre and post-operative orthopedic surgery patients. The study, which was published in the August edition of the peer-reviewed journal Pain Medicine, concludes that IV ibuprofen significantly decreased pain and morphine use when compared with placebo.

31 Aug 2010

Gastroenterology News and Research

Further Reading

New interventional technique effective for controlling hepatic arterial hemorrhage after PD

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Sun Pharmaceutical announces expiration of Tender Offer for purchase of Taro Pharmaceutical shares

Arthritis Foundation, Takeda launch Gout Living educational campaign

Merit Medical Systems acquires BioSphere Medical

IASIS Healthcare signs agreement to acquire Brim Holdings

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Spirus Medical obtains Japanese marketing approval for ENDO-EASE line of endoscopy devices

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

NIH expands funding for Baylor College of Medicine Human Microbiome Project

Israeli Supreme Court dismisses Taro's appeal in favor of Sun Pharma

GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Researchers dispute study findings that show greater incidence of surgery for children with CD

GI Dynamics, Elemental Healthcare sign agreement for distribution of EndoBarrier Gastrointestinal Liner

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

Tooth brush in a teenager’s stomach

Study: IV ibuprofen decreases pain, morphine use in pre and post-operative orthopedic surgery patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News